Tracy Taylor
Psychiatric/Mental Health · Longview, TXNPI 1740405711
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 782 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,546, 2.7 times the $1,698 reported in 2021. Among psychiatric/mental health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 782 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$2K
- Vanda Pharmaceuticals Inc.$2K
- AbbVie$2K
- Alkermes, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- plus $4K from 21 others
What the payments were for
- Food & beverage$13,94297%
- Education$4573%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 108 | $2,476 |
| Teva Pharmaceuticals USA, Inc. | 160 | $2,341 |
| Vanda Pharmaceuticals Inc. | 82 | $1,642 |
| AbbVie | 103 | $1,569 |
| Alkermes, Inc. | 81 | $1,383 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 36 | $1,049 |
| Otsuka America Pharmaceutical, Inc. | 52 | $971 |
| E.r. Squibb & Sons, L.L.C. | 26 | $419 |
| Johnson & Johnson | 16 | $399 |
| Supernus Pharmaceuticals, Inc. | 26 | $349 |
| Lundbeck LLC | 19 | $340 |
| Sunovion Pharmaceuticals Inc. | 18 | $283 |
| Axsome Therapeutics, Inc. | 12 | $280 |
| Idorsia Pharmaceuticals US Inc | 13 | $243 |
| Indivior Inc. | 6 | $146 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $76 |
| Eisai Inc. | 3 | $75 |
| Noven Therapeutics, LLC | 4 | $63 |
| Abiomed | 2 | $60 |
| OWP Pharmaceuticals, Inc. | 2 | $50 |
| Merck | 2 | $45 |
| Avanir Pharmaceuticals, Inc. | 2 | $34 |
| Harmony Biosciences LLC | 1 | $27 |
| Braeburn Inc. | 1 | $26 |
| Amgen | 1 | $19 |
| TG Therapeutics, Inc. | 1 | $19 |
| Sage Therapeutics, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$408
- UZEDY$237
- CAPLYTA$225
- INGREZZA$140
- Fanapt$125
- VRAYLAR$125
- INVEGA SUSTENNA$111
- INVEGA TRINZA$111
- Austedo XR$109
- AUSTEDO$104
- ARISTADA INITIO$102
How this compares
$14,399 in reported general payments places this provider in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 87 | $723,334 |
| Austedo XrDeutetrabenazine | 60 | $353,428 |
| RexultiBrexpiprazole | 144 | $224,881 |
| VraylarCariprazine Hcl | 128 | $201,369 |
| LybalviOlanzapine/Samidorphan Malate | 98 | $156,710 |
| CaplytaLumateperone Tosylate | 49 | $84,199 |
| BelsomraSuvorexant | 140 | $64,251 |
| TrintellixVortioxetine Hydrobromide | 87 | $45,934 |
| AuvelityDextromethorphan Hbr/Bupropion | 41 | $45,114 |
| Abilify MaintenaAripiprazole | 14 | $39,722 |
| Nurtec OdtRimegepant Sulfate | 22 | $39,360 |
| AristadaAripiprazole Lauroxil | 11 | $32,287 |
| QuviviqDaridorexant Hcl | 58 | $29,889 |
| FanaptIloperidone | 15 | $17,953 |
| Aripiprazole | 187 | $13,936 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $2,476 | $723,33487 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $2,341 | $353,42860 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $971 | $264,603158 claims |
| AbbVieVraylar | $1,569 | $201,369128 claims |
| Alkermes, Inc.Lybalvi, Aristada | $1,383 | $188,998109 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,049 | $84,19949 claims |
| MerckBelsomra | $45 | $64,251140 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $76 | $45,93487 claims |
| Axsome Therapeutics, Inc.Auvelity | $280 | $45,11441 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $243 | $29,88958 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,642 | $17,95315 claims |
| Eisai Inc.Dayvigo | $75 | $9,35028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Other psychiatric/mental health in Longview
- Tracy HicksLongview$684K
- Wendy RogersLongview$13K
- Natalie TellezHouston$602K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Victor IlogEl Paso$167K
- Lisa ShamblinGrapevine$163K
- Monique GonzalezSan Antonio$126K
- Marguerite AddisonWaco$118K
- Komi Kokou-AbiRound Rock$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.